Lonza Expands Conjugation Facility with Two Additional Manufacturing Suites
The expansion of bioconjugation capabilities will provide development and manufacturing capacity for pre-clinical to commercial supply
1500m
2 of manufacturing space will include two additional production suites in addition to the necessary manufacturing-related infrastructure
A significant increase of process and analytical development capacity will enable Lonza to offer expertise to a broad customer base
Quote from Iwan Bertholjotti, Director Commercial Development Bioconjugates, Lonza: Lonza started to offer CDMO services for antibody-drug conjugates (ADCs) back in 2006 and we now manufacture the majority of the currently commercially approved ADCs. The field goes beyond ADC s and Lonza has the expertise to support customers bringing a range of different bioconjugates to market. The latest investment in additional bioconjugation development and manufacturing capacity is well aligned with other curre